Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus PULMOLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus PULMOLITE.
HIPPURAN I 131 vs PULMOLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
PULMOLITE is a leukotriene receptor antagonist (LTRA) that selectively and competitively inhibits the cysteinyl leukotriene (CysLT1) receptor in the human airway, thereby reducing bronchoconstriction, mucus secretion, and eosinophilic infiltration.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
Adults: 200 mg intravenously every 12 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Terminal elimination half-life: 12 hours (range 10–14 h) in adults with normal renal function (CrCl >90 mL/min); prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Primarily renal (80%) as unchanged drug; 15% fecal via biliary excretion; 5% metabolized.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical